Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.

Abstract

BACKGROUND:

Until now no confirmatory clinical trial in children suffering from nonneurogenic overactive bladder (OAB) and urinary incontinence could demonstrate superiority for antimuscarinics over placebo.

OBJECTIVES:

The following study was conducted to prove efficacy and tolerability of propiverine compared to placebo.

DESIGN, SETTING, AND PARTICIPANTS:

A randomized, double-blind, placebo-controlled phase 3 trial with parallel-group design in children aged 5-10 yr was performed. Prior to the 8-wk medical therapy urologic baseline diagnostics, a 3-wk lifestyle advice (urotherapy) was established.

INTERVENTION:

After re-evaluation of in- and exclusion criteria and uroflowmetry, only children fulfilling the requested criteria were allocated to a body-weight-adjusted therapy (10 or 15 mg propiverine twice daily or corresponding placebo).

MEASUREMENTS:

Efficacy parameters derived from bladder diary and a micturition volume protocol. Decrease in voiding frequency per day was chosen as primary efficacy parameter; secondary endpoints included voided volume and incontinence episodes. A safety assessment was conducted.

RESULTS AND LIMITATIONS:

Of 171 randomized children, 87 were treated with propiverine and 84 with placebo. The primary efficacy parameter showed a decrease in voiding frequency (-2.0 episodes for propiverine versus -1.2 for placebo; p=0.0007). Superiority could also be demonstrated for voided volume (31.4 vs. 5.1 ml; p<0.0001) and incontinence episodes (-0.5 vs. -0.2 episodes per d; p=0.0005). The trial design did not allow for separate evaluation of the effect of urotherapy prior to medical treatment. Propiverine was well-tolerated in children. Altogether 23% of side-effects were reported for propiverine and 20% for placebo.

CONCLUSIONS:

This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence. An important additional factor for the success of the trial was a modified trial design with previous urotherapy.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT00603343.

• Authors: Daniela Marschall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, Maximilian Stehr, Christian Radmayr, Ulla Sillén, Gerhard Strugala
• Journal: European urology (Eur Urol) Vol. 55 Issue 3 Pg. 729-36 (Mar 2009) ISSN: 1873-7560 [Electronic] Switzerland
• PMID: 18502028 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Benzilates
• Cholinergic Antagonists
• propiverine

Topics

• Benzilates (therapeutic use)
• Child
• Cholinergic Antagonists (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Urinary Bladder, Overactive (drug therapy)
• Urinary Incontinence (drug therapy)